Columbia University

Technology Ventures

Almirall, S.A. Seeks Novel Immune-Inflammatory Targets, Pathways, and Therapies

Deadline: 
Monday, August 26, 2019 - 5:30pm to Monday, September 30, 2019 - 5:30pm

Almirall, S.A. is looking to sponsor research collaborations investigating novel targets, pathways, or therapeutic candidates relating to chronic immune-inflammatory diseases. Academics and university departments are invited to submit relevant, non‑confidential research proposals using the application form linked below. The team at Almirall are interested in sponsoring early-stage research programmes focused on target identification and validation, through to later stage applications progressing therapeutic opportunities into clinical settings.

Submissions will be assessed and, where appropriate, teams selected for funding of up to €250k per project in early November 2019.

Disease interest
Of highest priority are chronic immune-inflammatory skin diseases like atopic dermatitis, psoriasis, lichen planus, hidradenitis suppurativa, vitiligo or alopecia areata, as well as orphan diseases such as pemphigus vulgaris, epidermolysis bullosa or bulloid pemphigus.

However, projects in chronic immune-inflammatory diseases from other therapeutic areas (rheumatoid arthritis, multiple sclerosis, IBD, etc) would also be in scope provided the mechanisms/targets/pathways are common (they are not organ-specific).
 
Therapeutic opportunities
  • Modalities of interest: Of highest priority are biologics, novel chemical entities, and gene therapy approaches, though other approaches will be considered
  • Development stage: Basic research through to late pre‑clinical development
Jurisdictions of interest
Worldwide
 
Submissions information
Please submit research proposals to techventures@columbia.edu using the attached template by Sept. 30th, 2019.